Summary:
In children and adults with type 1 diabetes (T1D), automated insulin delivery (AID) using MiniMed™ 670G or 770G systems significantly improved HbA1c and reduced time spent in hypoglycemia compared to multiple daily injections (MDI) with or without continuous glucose monitoring, though it was associated with no major increase in severe hypoglycemia or diabetic ketoacidosis rates.
| PICO | Description |
|---|---|
| Population | Children and adults aged 2–80 years diagnosed with type 1 diabetes, classified into two subgroups based on baseline HbA1c levels (>8.0% and ≤8.0%), across 32 international centers. |
| Intervention | Automated insulin delivery (AID) using MiniMed™ 670G or 770G insulin pump systems over a 6-month period. |
| Comparison | Multiple daily injections (MDI) with or without continuous glucose monitoring (CGM). |
| Outcome | AID significantly reduced HbA1c by a mean of -0.7% (95% CI: -1.1 to -0.3, P = 0.0002) in participants with baseline HbA1c >8.0%, and decreased %TBR <70 mg/dL by 4.8% (95% CI: -6.4 to -3.1, P<0.001) for those with baseline HbA1c ≤8.0%. Severe hypoglycemia and DKA rates were low and within safety targets. |
Clinical Context
Automated insulin delivery systems represent a transformative advancement in type 1 diabetes management, integrating continuous glucose monitoring with insulin pump therapy through algorithmic control of basal insulin delivery. These hybrid closed-loop systems automatically adjust background insulin rates based on real-time glucose readings, reducing the cognitive burden of diabetes management while improving glycemic control. Despite growing adoption, direct randomized comparisons between AID and multiple daily injections have been limited, as most AID trials compared against standard pump therapy. Many patients with T1D worldwide continue using MDI regimens, and understanding the magnitude of benefit from transitioning to AID informs clinical recommendations and resource allocation decisions. This multinational randomized trial enrolled a broad population across age groups and baseline glycemic control levels to evaluate whether AID provides clinically meaningful improvements over MDI with or without continuous glucose monitoring.
Clinical Pearls
- AID produced a clinically significant HbA1c reduction of 0.7% in participants with elevated baseline HbA1c above 8.0%, representing meaningful improvement in long-term glycemic control.
- For participants with well-controlled baseline HbA1c at or below 8.0%, AID’s primary benefit was a 4.8 percentage point reduction in time below 70 mg/dL, substantially decreasing hypoglycemia exposure.
- The differential benefits based on baseline control suggest AID improves whatever aspect of glucose management is most problematic for individual patients.
- Safety outcomes including severe hypoglycemia and diabetic ketoacidosis rates remained low and comparable between groups, confirming AID does not introduce new safety concerns.
Practical Application
Clinicians should consider AID as a preferred management option for patients with type 1 diabetes across the glycemic control spectrum. For patients with suboptimal control on MDI, AID offers substantial HbA1c improvement that could reduce long-term complication risk. For patients already achieving target HbA1c but experiencing problematic hypoglycemia, AID provides meaningful protection against low glucose events. Insurance coverage and patient education requirements remain practical barriers to AID adoption that clinicians must address through advocacy and comprehensive training programs. Patients transitioning from MDI to AID require thorough education on system operation, infusion site management, and troubleshooting. The international scope of this trial supports generalizability across diverse healthcare settings and populations.
Broader Evidence Context
These findings strengthen the evidence base supporting AID as a standard of care for type 1 diabetes management. Prior trials predominantly compared AID against sensor-augmented pump therapy, demonstrating incremental benefits. This study’s comparison against MDI demonstrates larger effect sizes, reflecting the greater technology gap between injection therapy and automated delivery. The results align with real-world registry data and observational studies showing improved outcomes with AID adoption. Professional organizations including the American Diabetes Association increasingly recommend AID technology for appropriate candidates, and this trial provides randomized evidence supporting those recommendations. The inclusion of children as young as 2 years extends applicability to pediatric populations where diabetes management presents particular challenges.
Study Limitations
- The 6-month study duration may not capture long-term sustainability of glycemic improvements or potential technology fatigue effects.
- Participants could not be blinded to treatment assignment given the visible nature of pump therapy, potentially introducing performance bias.
- The MDI comparator group included participants with and without CGM, creating heterogeneity that could affect interpretation.
- Industry sponsorship by the device manufacturer warrants consideration of potential conflicts of interest.
- Cost-effectiveness and quality of life outcomes were not primary endpoints, leaving questions about value and patient experience beyond glycemic metrics.
Bottom Line
Automated insulin delivery using MiniMed 670G/770G systems significantly improves HbA1c in type 1 diabetes patients with suboptimal control and reduces hypoglycemia in those already well-controlled, compared to multiple daily injections. Clinicians should recommend AID technology for appropriate patients across age groups and baseline glycemic control levels.
Source: Jendle, Johan H., et al. “Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.” Read article here.
